Endpoints News
CSL's $5B write-down Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
Mon T W Th F
11 May, 2026
US Pharma and Biotech Summit - May 14, 2026
Just announced: A senior FDA official joins the conversation at the US Pharma & Biotech Summit. Policy shifts, regulatory unknowns, a dealmaking environment that won't sit still — join FT Live and Endpoints News for the conversations that will define what comes next.
presented by Parexel Biotech
Mov­ing be­yond sci­ence to ac­cess: Solv­ing the ac­cess im­per­a­tive
SPOTLIGHT
‘Pharma, not really’: Why AI’s top young talent isn’t interested in a career at big drugmakers
ENDPOINTS NEWS
news
European regulators greenlight first clinical test of GLP-1 gene therapy
ENDPOINTS NEWS
CSL sinks to nine-year low on revenue warning, $5B write-down
ENDPOINTS NEWS
Trump plans to fire Makary from FDA role, according to reports
ENDPOINTS NEWS
Endpoints webinars
May 12
10:30 am ET
Rules of engagement: How G3BP2 paves the way to rationalize novel degrons
Thermo Fisher
May 20
11:00 am ET
Application of Simple Western to analysis of antibody target affinity and specificity
Bio-Techne
LGBTQ+ LEADERSHIP IN 2026
LGBTQ+ diversity drives innovation in biopharma — but transgender and non-binary professionals face rising challenges. Endpoints is going live with our fourth annual special report celebrating the honorees giving voice and visibility while forging ahead across life sciences. Join us.
in case you missed it
1.
Daiichi Sankyo posts 'extraordinary loss' of nearly $1B after overestimating need for ADC capacity
ENDPOINTS NEWS
2.
Updated: Odyssey CEO talks about $279M IPO and building a 'permanent' biotech
ENDPOINTS NEWS
3.
Peer Review
Natalie Holles' next move after Third Harmonic shutdown; Mark Alles passes the torch at ADC biotech
ENDPOINTS NEWS
4.
Capricor sues Nippon Shinyaku over Duchenne drug 'pricing flaw' and launch prep
ENDPOINTS NEWS
5.
Astellas touts data from early test of stem cell-derived eye therapy
ENDPOINTS NEWS
6.
News Briefing
FDA delays Leqembi decision; Artiva raises $300M on RA data; Pharvaris prices offering
ENDPOINTS NEWS
7.
Aging and the narrowing of scientific innovation
Science Magazine
8.
Surge in fake citations uncovered by audit of 2.5 million biomedical science papers
NATURE
Reynald Castaneda
.

In case you missed it, Andrew Dunn wrote an insightful look at why AI talent is not flocking to biopharma to start their careers. Find out more here.
.
Reynald Castaneda
Deputy Editor, Endpoints News
Endpoints News